Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Ovid Therapeutics Announces Five Poster Presentations on TAK-935/OV935 at the American Epilepsy Society 71st Annual Meeting


Posted on: 21 Nov 17

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it will present five poster presentations on TAK-935/OV935 at the American Epilepsy Society (AES) 71st Annual Meeting, taking place from December 1-5, 2017, at the Walter E. Washington Convention Center in Washington, D.C.

Details of the poster presentation are listed below.

Title: Clinical Trial Simulations Using a Pharmacokinetic/Enzyme Occupancy/Pharmacodynamic Model of TAK-935, a Cholesterol 24S-hydroxylase Inhibitor
Abstract ID: 344434
Session: Poster Session 1
Date and Time: Saturday, December 2, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

Title: Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of TAK-935 in Healthy Subjects
Abstract ID: 344521
Session: Poster Session 2
Date and Time: Sunday, December 3, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of TAK-935 in Healthy Subjects
Abstract ID: 344533
Session: Poster Session 2
Date and Time: Sunday, December 3, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

Title: Evaluation of pharmacodynamic effects of cholesterol 24-hydroxylase inhibitor TAK-935 and its target engagement in animals
Abstract ID: 344659
Session: Poster Session 2
Date and Time: Sunday, December 3, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

Title: Inhibition of cholesterol 24-hydroxylase is a novel pharmacological strategy for epilepsy treatment
Abstract ID: 344660
Session: Poster Session 2
Date and Time: Sunday, December 3, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

About Rare Epilepsies

Developmental and/or epileptic encephalopathies are a group of rare epilepsies that cause significant morbidities for patients and their families beyond what might be expected from the underlying pathology alone and can worsen over time. Developmental and/or epileptic encephalopathies typically present early in life and are often associated with severe cognitive and developmental impairment in addition to frequent seizures throughout the person’s lifetime. These disorders vary in their age of onset, developmental outcome, etiologies, neuropsychological deficits, electroencephalographic (EEG) patterns, seizure types and prognosis.

Despite the availability of medicines for epilepsy, few treatment options are available for epileptic encephalopathies, and novel therapies are needed.

About TAK-935/OV935

TAK-935/OV935, which is being studied in rare epilepsies, is a potent, highly-selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). CH24H is predominantly expressed in the brain, where it plays a central role in cholesterol homeostasis. CH24H converts cholesterol to 24HC, which then exits the brain into the blood plasma circulation. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel, implying its potential role in central nervous system diseases such as epilepsy. To Ovid’s knowledge, TAK-935/OV935 is the only molecule with this mechanism of action in clinical development.

TAK-935/OV935 has been tested in preclinical models to provide data to support the advancement of the drug into human clinical studies in patients suffering from rare epilepsy syndromes. A novel proprietary PET ligand, developed by Takeda and Molecular Neuroimaging, LLC (MNI), has been used to determine target occupancy of TAK-935/OV935 in the brain. In addition, TAK-935/OV935’s effect on CH24H enzyme activity in the brain has been assessed by following measurable reductions in the plasma concentration of 24HC.

TAK-935/OV935 has completed four Phase 1 clinical studies, which have assessed tolerability and target engagement at doses believed to be therapeutically relevant. TAK-935/OV935 is being co-developed by Ovid and Takeda Pharmaceutical Company Limited.

About Ovid Therapeutics

Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid has initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome and a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies and has initiated a Phase 1b/2a trial of OV935.

For more information on Ovid, please visit http://www.ovidrx.com/.

Contacts
Investors:
Burns McClellan
Steve Klass, 212-213-0006
Sklass@burnsmc.com   

Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
katie@purecommunicationsinc.com   

GlobeNewswire
globenewswire.com

Last updated on: 21/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.